Table 3.
PEP regimen and alternative treatment regimen recommended by CDC
Population | PEP regimen(preferred) | Alternative regimen |
---|---|---|
Adults and adolescents (≥ 13 years) with normal renal function (Cr CL ≥ 60 mL/min) |
Tenofovir disoproxil fumarate 300 mg once daily or emtricitabine 200 mg once daily + Dolutegravir 50 mg once daily or Raltegravir 400 mg twice daily |
Tenofovir disoproxil fumarate 300 mg once daily or emtricitabine 200 mg once daily + Darunavir 800 mg (as two, 400-mg tablets) once daily and ritonavirb 100 mg once daily |
Adults and adolescents (≥ 13 years) with renal dysfunction (Cr CL ≤ 59 mL/min) |
Zidovudine and Lamivudine, with both doses adjusted to degree of renal function + Raltegravir 400 mg twice daily + Dolutegravir 50 mg once daily or Raltegravir 400 mg twice daily |
Zidovudine and Lamivudine, with both doses adjusted to degree of renal function + Darunavir 800 mg (as two 400-mg tablets) once daily + Ritonavirb 100 mg once daily |
Children aged 2–12 years | Tenofovir DF, emtricitabine, and Raltegravir, with each drug dosed to age and weight |
Zidovudine and Lamivudine + Raltegravir or lopinavir/ritonavir + Raltegravir (lopinavir/ritonavir dosed to age and weight) |
Cr CL, creatinine clearance